why choose us

Clinical Trials Search

Showing 18,970 of 132,963 result(s)
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and;or Metastatic Breast Cancer

Status: Completed

Condition: Breast Cancer

Interventions: Not Applicable since observational study

Date: 2022-10-20

Improving Exercise Capacity With a Tailored Physical Activity Intervention

Status: Completed

Condition: Non Hodgkin Lymphoma

Interventions: 1-2 sessions per week consisting of slow 15 minute aerobic warm, 20 minutes of strength training, 15 minutes progressive intensity aerobic exercise an

Date: 2022-10-20

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Status: ACTIVE_NOT_RECRUITING

Condition: Post COVID-19 Condition

Interventions: 100 to 400 mg twice weekly

Date: 2022-10-20

Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes

Status: Completed

Condition: Burn Wound

Interventions: ICG is a well, known, FDA-approved dye

Date: 2022-10-20

School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska

Status: Completed

Condition: Hearing Loss

Interventions: Schools in the control condition will use standard referral, as determined by the school district.
Standard referral is typically a letter home f

Date: 2022-10-20

Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin

Status: Completed

Condition: Acute Bacterial Skin and Skin Structure Infection

Interventions: Oritavancin for IV infusion

Date: 2022-10-20

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET;CT in Patients With Pheochromocytoma and Paraganglioma

Status: Completed

Condition: Pheochromocytoma

Interventions: A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography;computed tomography (PET;CT) scan will be done prior to surgery

Date: 2022-10-20

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Status: Completed

Condition: Unresectable or Metastatic Microsatellite Stable;Mismatch Repair Proficient Colorectal Cancer

Interventions: Low dose intravenously (IV) once every 3 weeks.

Date: 2022-10-20

The Preliminary Effects of Empower@Home

Status: ACTIVE_NOT_RECRUITING

Condition: Depression

Interventions: Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical a

Date: 2022-10-20